← Back to feedRead original →
VERIFIEDMint Companies·neutral
Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha
AI Summary
- ·Glenmark is pivoting towards global drug innovation with a 10-year plan.
- ·The strategy involves licensing deals, partnerships, and commercialization in emerging markets.
- ·Chairman Glenn Saldanha outlined the company's future direction.